
Allakos Unveils Promising Phase 1 Results of AK006 for Chronic Hives Treatment and Company Restructuring Announcement
A New Setback for Allakos: AK006 Fails to Demonstrate Therapeutic Activity in CSU In a recent press release, Allakos, a clinical-stage biotechnology company, announced that their lead investigational drug, AK006, did not demonstrate therapeutic activity in the Complete Synovitis Ulcerosus Canine Model (CSU) of atopic canine dermatitis. This model is widely used to evaluate the…